{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune&page=5",
    "query": {
      "condition": "Immune",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 22367,
    "total_pages": 2237,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T01:50:15.863Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00146328",
      "title": "Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Tipranavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 997,
      "start_date": "2001-04",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-03-06",
      "last_synced_at": "2026-10-27T01:50:15.863Z",
      "location_count": 86,
      "location_summary": "Phoenix, Arizona • Berkeley, California • Fountain Valley, California + 56 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00146328"
    },
    {
      "nct_id": "NCT03190265",
      "title": "Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "GVAX Pancreas Vaccine",
          "type": "DRUG"
        },
        {
          "name": "CRS-207",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2017-12-14",
      "completion_date": "2023-08-23",
      "has_results": true,
      "last_update_posted_date": "2024-08-07",
      "last_synced_at": "2026-10-27T01:50:15.863Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03190265"
    },
    {
      "nct_id": "NCT03228667",
      "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Small Cell Lung Cancer",
        "Urothelial Carcinoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Merkel Cell Carcinoma",
        "Melanoma",
        "Renal Cell Carcinoma",
        "Gastric Cancer",
        "Cervical Cancer",
        "Hepatocellular Carcinoma",
        "Microsatellite Instability",
        "Mismatch Repair Deficiency",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "N-803 + Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Avelumab",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Pembrolizumab + PD-L1 t-haNK",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Nivolumab + PD-L1 t-haNK",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Atezolizumab + PD-L1 t-haNK",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Avelumab + PD-L1 t-haNK",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Durvalumab + PD-L1 t-haNK",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Docetaxel + Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Docetaxel + Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2018-12-11",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-14",
      "last_synced_at": "2026-10-27T01:50:15.863Z",
      "location_count": 35,
      "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 31 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "El Segundo",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03228667"
    },
    {
      "nct_id": "NCT00874900",
      "title": "Asthma Learning Project",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Educational game",
          "type": "OTHER"
        },
        {
          "name": "Educational game + motivational interview",
          "type": "OTHER"
        },
        {
          "name": "Motivational interview",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Seattle Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "15 Years",
        "sex": "ALL",
        "summary": "7 Years to 15 Years"
      },
      "enrollment_count": 120,
      "start_date": "2008-12",
      "completion_date": "2013-05",
      "has_results": false,
      "last_update_posted_date": "2011-07-08",
      "last_synced_at": "2026-10-27T01:50:15.863Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00874900"
    },
    {
      "nct_id": "NCT00228592",
      "title": "HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis B",
        "Liver Transplantation"
      ],
      "interventions": [
        {
          "name": "HepeX-B",
          "type": "DRUG"
        },
        {
          "name": "Hepatitis B Immune Globulin (HBIg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": "2005-08",
      "has_results": false,
      "last_update_posted_date": "2007-02-13",
      "last_synced_at": "2026-10-27T01:50:15.863Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • San Francisco, California • Rochester, Minnesota + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00228592"
    },
    {
      "nct_id": "NCT02001064",
      "title": "Care4Today v2.0 Application for Improving Adherence to HIV Medications",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV",
        "AIDS"
      ],
      "interventions": [
        {
          "name": "Care4Today v2.0 mobile application + electronic monitoring of adherence",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2013-10",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2021-07-29",
      "last_synced_at": "2026-10-27T01:50:15.863Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02001064"
    },
    {
      "nct_id": "NCT02297932",
      "title": "Physical Activity in Multiple Sclerosis (MS): A Novel Approach to Study Outcomes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Strength training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Stretching",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Kessler Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 18,
      "start_date": "2014-11",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2017-08-18",
      "last_synced_at": "2026-10-27T01:50:15.863Z",
      "location_count": 1,
      "location_summary": "West Orange, New Jersey",
      "locations": [
        {
          "city": "West Orange",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02297932"
    },
    {
      "nct_id": "NCT00147498",
      "title": "Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "CP-690,550",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 264,
      "start_date": "2005-01",
      "completion_date": "2006-06",
      "has_results": true,
      "last_update_posted_date": "2013-01-30",
      "last_synced_at": "2026-10-27T01:50:15.863Z",
      "location_count": 24,
      "location_summary": "Upland, California • Clearwater, Florida • Miami, Florida + 19 more",
      "locations": [
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "New Port Richey",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00147498"
    },
    {
      "nct_id": "NCT02093663",
      "title": "Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "MMX Mesalamine/Mesalazine (Low Dose)",
          "type": "DRUG"
        },
        {
          "name": "MMX Mesalamine/Mesalazine (High Dose)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 107,
      "start_date": "2014-12-12",
      "completion_date": "2018-11-28",
      "has_results": true,
      "last_update_posted_date": "2021-06-09",
      "last_synced_at": "2026-10-27T01:50:15.863Z",
      "location_count": 9,
      "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Newton, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Newton",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02093663"
    },
    {
      "nct_id": "NCT06329414",
      "title": "Acceptability and Feasibility of Transcranial Magnetic Stimulation (TMS) for Depression in Multiple Sclerosis",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis",
        "Major Depressive Disorder",
        "Treatment Resistant Depression"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 12,
      "start_date": "2024-01-16",
      "completion_date": "2026-01",
      "has_results": false,
      "last_update_posted_date": "2024-03-25",
      "last_synced_at": "2026-10-27T01:50:15.863Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06329414"
    }
  ]
}